Trending News

Novo Nordisk says Alzheimer's drug trial fails to meet main goal

Novo Nordisks shares fell 10% after the company said its oral semaglutide drug Rybelsus failed to meet the main goal in late-stage trials testing whether it could slow cognitive decline in early Alzheimers patients. The setback dims hopes for expanding GLP-1 medicines into a major new market beyond obesity and diabetes, reinforcing scepticism over Novos Alzheimers ambitions.